Fairmount Funds (director, 10% owner) invests $20M in VRDN shares near 52-week lows as stock rebounds from deeper weakness.
Fairmount Funds Management—a director and 10% beneficial owner of Viridian Therapeutics—deployed approximately $20 million to purchase over 1.1 million shares, expanding its position by roughly a third. This is the fund's fourth open-market purchase of VRDN stock in 36 months, signaling persistent conviction despite the company's unprofitable status and recent operational challenges (quarterly revenue cratered from full-year levels). The timing is noteworthy: the stock is trading well below its 52-week high after a sharp recent decline, but has recovered modestly over the past month—suggesting Fairmount may be accumulating during a period of relative stabilization after severe weakness. Fairmount's broader track record shows a strong preference for buying (16 prior purchases across all holdings versus only 3 sales in 36 months), though the fund's returns on prior open-market buys have been mixed, with short-term gains not translating to sustained long-term outperformance. Without measurable outcome data from Fairmount's three prior VRDN purchases, it remains unclear whether this repeated buyer has been right about the stock before—a material gap in assessing whether this fresh $20 million deployment reflects learned insight or persistent conviction despite mixed results.